FreshLeaf Analytics News

Read the latest ideas, insights and observations on the Australian Medicinal Cannabis Industry from the team at FreshLeaf Analytics.

NZ recreational cannabis bill released
01
May

NZ recreational cannabis bill released – prioritises social good over profits

NZ recreational cannabis bill released – prioritises social good over profits New Zealanders will go to the polls on September 19 to vote for their federal government as well as two contentious referenda: voluntary assisted dying and recreational cannabis. The full recreational cannabis bill is now published and the government has provided an accompanying plain-English...
Read More
CBD available for sale in pharmacies
24
Apr

Australian government proposes CBD be made available for retail sale

Australian government proposes CBD be made available for retail sale Today the Therapeutic Goods Administration released the Department of Health-initiated proposal to make low-dose CBD available for sale in pharmacies as a Schedule 3 drug. The proposed changes would allow the sale of pure CBD (with 2% or less other cannabinoids) to adults in packets...
Read More
Aust-Senate-website
25
Mar

Australian Senate Committee tables recommendations from inquiry into barriers to medical cannabis

Australian Senate Committee tables recommendations from inquiry into barriers to medical cannabis The Community Affairs and References Committee tabled their report today (25/3/20) on the inquiry into barriers to medical cannabis patient access in Australia.  FreshLeaf has covered this inquiry extensively and attended the public hearings, so if you’re interested in the recent history of...
Read More
FreshLeaf Analytics Global Recession
17
Mar

What does a global recession mean for the cannabis industry?

What does a global recession mean for the cannabis industry? COVID-19 is wreaking havoc on the global economy. And there are genuine concerns about a prolonged economic downturn, unlike any other in recent memory. People are worried about their health and for their families, as well as their businesses and jobs. The performance and survival...
Read More
The Therapeutic Goods Administration (TGA)
12
Mar

Medical cannabis quality crack-down

Medical cannabis quality crack-down   The Therapeutic Goods Administration (TGA) has announced it will be ramping up the number of quality audits it conducts on imported medical cannabis products. This will include analytical testing to assess compliance with TGO93, the quality standard for cannabis products.  TGO93 requires products to have acceptable levels of pesticides, heavy...
Read More
ODC’s consultation
04
Feb

We attended the ODC’s consultation session on proposed medical cannabis license changes so you didn’t have to

We attended the ODC’s consultation session on proposed medical cannabis license changes so you didn’t have to The Office of Drug Control (ODC) held consultation sessions in three capital cities over the last week seeking feedback on their proposed changes to Australia’s commercial medical cannabis licensing system. FreshLeaf attended the Sydney workshop on February 3rd...
Read More
Freshleaf and TGA
30
Jan

The TGA is re-examining the clinical evidence for medical cannabis – including over-the-counter CBD

The TGA is re-examining the clinical evidence for medical cannabis – including over-the-counter CBD This is the third article in our series about the Department of Health’s submission to the Senate Inquiry into medical cannabis patient access. You can read the Department’s submission here. In December 2017 the TGA, in collaboration with several universities, produced...
Read More
FreshLeaf Analytics Graphic 3
29
Jan

Department of Health releases new medical cannabis patient access info

Department of Health releases new medical cannabis patient access info The TGA tends to avoid speaking about prescriptions because they have no direct oversight regarding scripts. Instead they focus on SAS-A/B approvals and AP notifications. These can be considered proxy figures for access. And if you have empirical data about prescriptions per approval, and empirical...
Read More

Leave us your info

and we will get back to you.